REG - Glanbia PLC - First Quarter 2025 Interim Management Statement

GlanbiaAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd7174Ga&default-theme=true

RNS Number : 7174G  Glanbia PLC  30 April 2025

FIRST QUARTER 2025 INTERIM MANAGEMENT STATEMENT

First quarter in line with expectations, full year guidance reiterated

30 April 2025 - Glanbia plc, the Better Nutrition company ("Glanbia" or the
"Group"), is issuing this Interim Management Statement for the three month
period ended 5 April 2025 ("first quarter", "the period", or "Q1 2025"). This
statement is issued in conjunction with the Group's Annual General Meeting
("AGM") which is being held today.

Highlights 1 

·     Q1 2025 Group performance in line with expectations;

·     Reiterating full year guidance of adjusted EPS 2  of 124 $cent - 130
$cent;

·     Group revenue growth of 7.2% (2.7% of which related to
acquisitions);

·   Performance Nutrition ("PN") revenue decline of -6.6% with Optimum
Nutrition revenue declining by -3.1%, primarily as a result of lower revenues
in the club and specialty channels in the US as anticipated, offsetting growth
in online/FDM channels and international markets;

·   Health & Nutrition ("H&N") revenue growth of 24.9% (of which
19.3% related to the acquisition of Flavor Producers), driven by strong volume
growth;

·     Dairy Nutrition ("DN") revenue growth of 18.9%, primarily as a
result of good demand for protein solutions and strong dairy market pricing;

·     €50 million share buyback on-going with €42.7 million
repurchased to date;

·     Good progress on mitigating short-term input cost inflation in PN;
and

·    Continued progress on the strategic agenda with group-wide
transformation programme ongoing, including the exit of non-core businesses,
to drive efficiencies and support the next phase of growth.

 

________________

 

 1  Current period reported revenues are not comparable with those of the
prior period reported numbers as a result of the amendment to the operating
model, separating the Glanbia Nutritionals business into two new divisions,
Health & Nutrition and Dairy Nutrition, hence for the prior period,
pro-forma numbers are used for comparative purposes, on a constant currency
basis throughout.

2 Adjusted Earnings Per Share ("EPS") on a constant currency basis.

 

Commenting today Hugh McGuire, Chief Executive Officer, said:

 

"I am pleased to report that Glanbia delivered a resilient performance during
the first quarter by delivering Group like-for-like revenue growth of 4.5%
whilst navigating macroeconomic volatility and short-term headwinds in our
Performance Nutrition division.

 

Our Health & Nutrition and Dairy Nutrition segments delivered a strong
performance. As previously announced, Performance Nutrition is facing
short-term challenges in the US club channel and we are offsetting this by
delivering good growth in our online and food, drug & mass channels and
international markets, which is supported by a strong innovation pipeline.

 

We have made good progress on our group-wide transformation programme which is
focused on delivering efficiencies, optimising our portfolio and maximising
long-term value for shareholders. Significant efforts have been made to reduce
the impact of input costs on the Group. We now have good visibility of costs
to the end of the year and we are reiterating our margin expectations for PN.

 

With the first quarter having progressed as planned, and whilst noting the
ongoing uncertainty in relation to direct tariffs, we are pleased to reiterate
our 2025 full year guidance of adjusted EPS(2) in the range of 124 $cent - 130
$cent (-11% to -7% constant currency)."

 

 

Summary revenue progression (all commentary is on a constant currency basis)

                                Summary of Q1 2025 revenue progression versus prior year
                                Constant currency movement
                                Volume      Price       Like-for-like  Acquisition / Disposals  Total constant currency  Total

                                                                                                                         reported currency
 Performance Nutrition          (5.8%)      (0.8%)      (6.6%)         -                        (6.6%)                   (7.3%)
 Health & Nutrition             6.0%        (0.4%)      5.6%           19.3%                    24.9%                    23.7%
 Dairy Nutrition                3.6%        15.3%       18.9%          -                        18.9%                    18.9%
 Total wholly-owned businesses  (0.7%)      5.2%        4.5%           2.7%                     7.2%                     6.7%

 

In the three months ended 5 April 2025, wholly-owned revenue increased by 7.2%
compared to the same period in 2024. The main drivers of the revenue increase
were a price increase of 5.2% and an increase of 2.7% from acquisitions,
partially offset by a volume decrease of -0.7%.

Performance Nutrition

PN revenue declined by -6.6% in the first three months of 2025, driven by a
volume decrease of -5.8% and a price decrease of -0.8%. Excluding SlimFast and
Body & Fit, which have been designated as non-core and following a
decision to exit the businesses, PN revenue declined by -4.8%.

The volume decrease primarily related to lower revenues in the club and
specialty channels in the US as well as the continued negative impacts from
non-core brands, with PN Americas revenue declining by -13.2% and PN
International revenue increasing by 6.1%.

The revenue growth in PN International was driven by good volume growth across
primary markets, including Asia Pacific, with Optimum Nutrition continuing to
gain traction with consumers in key markets, supported by the continued
development of in-market capabilities.

Pricing decreased by -0.8% as a result of some tactical price reductions,
which offset price increases that were implemented in most international
markets during the first quarter.

Optimum Nutrition delivered US consumption 3  of 0.4%, with good growth in the
online and FDM channels offset by declines in the specialty and club channels.
The healthy lifestyle portfolio delivered US consumption(3) of -0.9% against a
strong comparative period.

Whey protein isolate has come off its peak pricing seen earlier this year and
whilst pricing still remains elevated, the Group has good visibility of input
costs through the end of the year, in line with previous expectations.

________________

 

3 Consumption growth is US measured channels and includes online, FDMC (Food,
Drug, Mass, Club) and specialty channels. Data compiled from published
external sources and Glanbia estimates for the 13 week period to 5 April 2025.

 

Health & Nutrition

Health & Nutrition is a leading global ingredients solutions business,
providing value added ingredient and flavour solutions to a range of
attractive, high-growth end markets. H&N revenue increased by 24.9%. This
was driven by a 6.0% increase in volume, a -0.4% decrease in price, and an
increase of 19.3% from the impact of the acquisition of Flavor Producers. The
volume growth was driven by a strong performance in both the premix and
flavour solutions businesses. The Flavor Producers business, acquired in April
2024, is performing well and the integration is on track.

 

Dairy Nutrition

Dairy Nutrition is the number one producer of whey protein isolate and the
number one producer of American-style cheddar cheese in the US and provides a
wide range of dairy and functional protein solutions. DN revenue increased by
18.9%. This was driven by a 3.6% increase in volume and a 15.3% increase in
price. The volume increase was driven by strong growth in protein solutions
and the pricing increase was driven by favourable dairy market pricing.

Transformation programme

The Group is focused on executing its group-wide transformation programme.
This is a three-year initiative expected to generate annual cost savings of at
least $50 million by 2027 by driving efficiencies across the new operating
model which will support the next phase of growth through three focused
divisions. Dairy Nutrition is on track to be stood up as a standalone business
by 1(st) July 2025 with a new CEO and leadership team. The exit of non-core
businesses is underway and the Group is focused on unlocking supply chain
efficiencies and accelerating digital transformation.

Share buyback

The Group commenced an initial €50 million share buyback programme on 16
December 2024. Between 16 December 2024 and 29 April 2025, Glanbia returned
€42.7 million to shareholders, repurchasing 3,489,320 ordinary shares on
Euronext Dublin at an average price of €12.23. The buyback will be
temporarily paused as the percentage of the Group's issued share capital held
by a significant shareholder is approaching 29.99%. The Group expects to
recommence the share buyback programme during the second quarter of 2025.

Financing

The Group's balance sheet remains in a strong position. Glanbia's net debt at
5 April 2025 was $578.8 million, an increase of $289.4 million versus the net
debt position at the end of Q1 2024, which primarily relates to the
acquisition of Flavor Producers, which closed in April 2024. At the end of the
period the Group had committed debt facilities of $1.3 billion.

2025 Outlook

The impacts of currently known direct tariffs have been largely mitigated and,
based on the current market environment and expectations for the remainder of
the year, the Group reiterates its guidance and expects to deliver adjusted
EPS in the range of 124 $cent - 130 $cent (-11% to -7% constant currency).

Annual General Meeting

Glanbia is holding its AGM in person at 11.00 a.m. (BST) today at the
Killashee Hotel, Naas, Co. Kildare, Ireland.

Board and Committee changes

Mr Senan Murphy will join the Group's Board today as a Non-Executive Director.
On appointment, Mr Murphy will also join the Audit and Sustainability Board
committees.        Mr Murphy will become Chairman of the Sustainability
committee on appointment. Also today, Ms Ilona Haaijer will step down from the
Audit Committee.

Ends

Cautionary statement

This announcement contains forward-looking statements. These statements have
been made by the Directors in good faith based on the information available to
them up to the time of their approval of this report. Due to the inherent
uncertainties, including both economic and business risk factors underlying
such forward-looking information, actual results may differ materially from
those expressed or implied by these forward-looking statements. The Directors
undertake no obligation to update any forward-looking statements contained in
this announcement, whether as a result of new information, future events, or
otherwise.

IMS conference call and webcast details

There will be an analysts' conference call and webcast presentation to
accompany this Interim Management Statement at 8.00 a.m. (BST) today. Please
access the webcast from the Glanbia website at
https://www.glanbia.com/investors/financial-calendar, where the presentation
can also be viewed or downloaded.

A replay of the call will be available for 30 days from this afternoon. Please
see the link below to the Investor Relations section of the Glanbia plc
website for details:

https://www.glanbia.com/investors/financial-calendar

For further information contact

Glanbia plc +353 (0)56 777 2200

Mark Garvey, Chief Financial Officer

Liam Hennigan, Group Company Secretary & Head of Investor
Relations:                        +353 (0)86 046 8375

Lauren O'Sullivan, Investor Relations Manager:
                                            +353 (0)85
741 7861

Martha Kavanagh, Director of Corporate Affairs:
                                              +353
(0)87 646 2006

 

(#_ftnref1)

(#_ftnref2)

(#_ftnref3)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  QRFPPUAPCUPAPUB